SLL: Clinical Trials

3 recruiting. 3 Phase 3.

By phase and status

Phase	Trials	Status
Phase 3	3	Recruiting 3

Follow SLL: new trials by email Literature Review of SLL trials Research Report on SLL

Trials (filtered) newest first · largest first

All 3 trials

Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.

Trial	Phase	Status	Sponsor	Enrollment	Start	Updated
ROCKET-CLL Global Phase 3 Study: Rocbrutinib vs Pirtobrutinib in cBTKi-Pretreated R/R CLL/SLL Rocbrutinib, Pirtobrutinib - CLL / SLL, CLL (Chronic Lymphocytic Leukemia)	Phase 3	Recruiting	Newave Pharmaceutical Inc	306	2026-04-23	2026-11-12
A Study of Tacabrutideg (BGB-16673) Compared to Investigator's Choice in Participants With Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma Previously Exposed to Both Bruton Tyrosine Kinase (BTK) and B-cell Leukemia/Lymphoma 2 Protein (BCL2) Inhibitors Tacabrutideg, Bendamustine, Idelalisib - CLL, Chronic Lymphocytic Leukemia	Phase 3	Recruiting	BeOne Medicines	250	2025-04-10	2026-11-12
A Study of Nemtabrutinib Plus Venetoclax vs Venetoclax + Rituximab (VR) in Second-line (2L) + Relapsed/Refractory (R/R) Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (CLL/SLL) (MK-1026-010/BELLWAVE-010). Nemtabrutinib, Venetoclax, Rituximab - Leukemia, Lymphocytic, Chronic, B-Cell, Leukemia, Chronic Lymphocytic	Phase 3	Recruiting	Merck Sharp & Dohme LLC	735	2023-08-08	2026-11-06

Narrower conditions

Leukemia, Lymphocytic, Chronic, B-Cell (3)  ·  Chromosome 17 deletion (1)  ·  Leukemia, B-Cell (1)  ·  Recurrence (1)

Broader conditions

Chronic Disease (3)  ·  Disease Attributes (3)  ·  Hematologic Diseases (3)  ·  Hemic and Lymphatic Diseases (3)  ·  Immune System Diseases (3)  ·  Immunoproliferative Disorders (3)  ·  Leukemia (3)  ·  Leukemia, Lymphoid (3)  ·  Lymphatic Diseases (3)  ·  Lymphoproliferative Disorders (3)  ·  Neoplasms (3)  ·  Neoplasms by Histologic Type (3)  ·  Pathologic Processes (3)  ·  Pathological Conditions, Signs and Symptoms (3)  ·  Leukemia, B-Cell (2)

Interventions

Rituximab (2)  ·  venetoclax (2)  ·  ARQ531 (1)  ·  Bendamustine Hydrochloride (1)  ·  idelalisib (1)  ·  pirtobrutinib (1)

Sponsors

BeOne Medicines (1)  ·  Merck Sharp & Dohme LLC (1)  ·  Newave Pharmaceutical Inc (1)

Countries

United States (3)  ·  Argentina (2)  ·  Australia (2)  ·  Brazil (2)  ·  Canada (2)  ·  France (2)  ·  Germany (2)  ·  Italy (2)  ·  Japan (2)  ·  Turkey (Türkiye) (2)  ·  United Kingdom (2)  ·  Belgium (1)  ·  Chile (1)  ·  Colombia (1)  ·  Czechia (1)